Abstract:To evaluate the impact of pathologic response of primary tumor on disease-free survival (DFS) and overall survival (OS) in patients with locally advanced breast cancer (LABC) and reached axillary pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). From January 2008 to June 2013, 210 patients who received NAC in Fudan University Shanghai Cancer Center and reached axillary pCR after operation were retrospectively analyzed regarding to the prognostic significance of achieving a pCR or not in primary tumor. Those patients were diagnosed as clinical stage II-III breast cancer and primary tumor and lymph nodes were confirmed by core needle biopsy before NAC. Clinical stage was assessed by physical examination and imaging procedures. Axillary lymph nodes and primary tumors response to NAC were assessed via histopathology after surgery. Axillary pCR was defined as no invasive lymph nodes were detected after axillary lymph nodes dissection or sentinel lymph node biopsy. No residual invasive carcinoma or only residual ductal carcinoma in situ (DCIS) in primary tumor tissue was considered as pCR in primary tumor. Patients were divided into two groups for statistical analysis, according to whether they reached pCR or not in primary tumor. The groups were compared in terms of DFS and OS. The median follow-up time was 35 months (range, 6-100 months). Median age of 210 patients was 50 years olds (range, 24-80 years old). 107 (51%) patients were hormone receptor positive and 72 (34.4%) of them were Her2 positive. All patients received NAC and 188 (89.5%) of whom received NAC based on paclitaxel and carboplatin, the median course was 4. 192 (91.4%) patients received postoperative chemotherapy and 151 (76.6%) patients received radiation therapy. Almost all hormone receptor positive patients (104/107) received hormone therapy and only 40.3% (29/72) Her2 positive patients received Herceptin therapy. Of all patients, 42.9% (90/210) reached pCR in primary tumor, who had favorable DFS compared with non-pCR ones (Hazard ratio: 0.4024, 95% confidence interval [CI] 0.1699-0.9530, P = 0.0658). OS didn’t show significant difference between two groups (HR: 0.2723, 95% [CI] 0.05391-1.3749, P = 0.2029). Postoperative radiation therapy significantly improved DFS in patients with residual tumor (HR: 0.2782, 95% [CI] 0.0777-0.9959, P = 0.0077), but didn’t improve OS (HR: 0.7971 95% [CI] 0.0719-8.8427, P = 0.8436). Because of relative low sample size in primary tumor pCR patients, radiation therapy improved neither DFS nor OS. Primary tumor pCR was a favorable factor for prognosis in patients who reached axillary pCR after NAC. Patients with residual tumor tend to have lower DFS compared with primary tumor pCR ones, but radiation therapy could improve DFS for them.

Analysis of the Predicted Factors of Pathological Complete Response (pcr) after Neoadjuvant Systemic Therapy in Primary Breast Cancer and the Prognostic Value of Pcr

[Factors Related with Pathological Complete Response of Neoadjuvant Chemotherapy in Primary Breast Cancer].

[Predictive factors of pathological complete response in primary human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy].

Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis

Development and Validation of a Novel Model for Predicting Prognosis of Non-PCR Patients After Neoadjuvant Therapy for Breast Cancer

Retrospective Analysis of Factors Impacting Efficacy of Patients with Later Stage Breast Cancer Receiving Neoadjuvant Therapy.

The Impact of Pathological Response of Primary Tumor in Patients with Locally Advanced Breast Cancer Who Reached Axillary Pathological Complete Response (pcr) after Neoadjuvant Chemotherapy

Impact of Pathological Response and Recurrence Pattern on the Survival of Patients Who Develop Recurrence from Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC).

Predictive Factors for Complete Pathological Response in Hormone Receptor-Negative Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Analysis of Factors Associated With Pathological Complete Response in Patients With HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy

Analysis on the factors related with the response of neoadjuvant therapy in primary breast cancer

Clinicopathological characteristics and survival analysis of different molecular subtypes of breast invasive ductal carcinoma achieving pathological complete response through neoadjuvant chemotherapy

Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy.

P2-12-18: A Prognostic Model Based on Node Status, Cathpesin-D and Ki-67 Predict the Outcome of Patients Failing To Achieve Pathological Complete Response after Anthracycline-Based Neoadjuvant Chemotherapy for Breast Cancer.

Factors influencing pathological complete response and tumor regression in neoadjuvant radiotherapy and chemotherapy for high-risk breast cancer

Pathological response and survival after neoadjuvant therapy for breast cancer: A 30-year study

18F-FDG PET/CT for early prediction of pathological complete response in breast cancer neoadjuvant therapy: a retrospective analysis.

Predictors of pathological complete response to neoadjuvant treatment in invasive breast cancer with different human epidermal growth factor receptor 2 (HER2) subcategories

Predictors of Response and Survival Outcomes of Triple Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

A Prognostic Model to Predict Outcome of Patients Failing to Achieve Pathological Complete Response after Anthracycline‐containing Neoadjuvant Chemotherapy for Breast Cancer